Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.30 |
| ▸ | TACR1 | P25103 | 2/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4357930 | 0.90 | CYP1A2 (0.36) | CTSDBACE1CYP1A2DPP4HCRTR1 | |
| SCHEMBL4357934 | 0.90 | CYP1A2 (0.36) | CTSDBACE1CYP1A2DPP4HCRTR1 | |
| SCHEMBL4356938 | 0.88 | BACE1 (0.42) | CTSDBACE1 | |
| SCHEMBL4356942 | 0.88 | BACE1 (0.42) | CTSDBACE1 | |
| SCHEMBL4359189 | 0.87 | CYP1A2 (0.32) | CTSDBACE1PDE4BCYP1A2CCNT1 | |
| SCHEMBL4359185 | 0.87 | CYP1A2 (0.32) | CTSDBACE1PDE4BCYP1A2CCNT1 | |
| SCHEMBL12741865 | 0.79 | MEN1 (0.39) | — | |
| SCHEMBL8294163 | 0.79 | MEN1 (0.39) | — | |
| SCHEMBL4362200 | 0.77 | BACE1 (0.41) | CTSDBACE1 | |
| SCHEMBL4362203 | 0.77 | BACE1 (0.41) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | CTSD 70/4885BACE1 2/4885PDE4B 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.